NSAIDs with Enterohepatic Recirculation and Associated Risks

Introduction to Enterohepatic Recirculation

• NSAIDs that undergo enterohepatic recirculation, such as diclofenac, sulindac, indomethacin, piroxicam, and ketorolac, are associated with significantly greater gastrointestinal toxicity due to prolonged gastric and duodenal mucosal exposure, as recommended by the American Gastroenterological Association 1

Cardiovascular Risk Profile

• The American Heart Association recommends that diclofenac carries a particularly high cardiovascular risk among NSAIDs that undergo enterohepatic recirculation, with a relative risk of vascular events = 1.63 (95% CI: 1.12-2.37) 2
• The American College of Cardiology states that the mortality risk associated with diclofenac is RR = 2.40 (95% CI: 2.09-2.80), the highest among commonly used NSAIDs 2

Gastroprotection Strategies

• The American Gastroenterological Association recommends that for patients requiring diclofenac who have GI risk factors, PPI co-therapy reduces endoscopic NSAID-related ulcers by approximately 90% 4
• The European Society for Clinical Gastroenterology and Hepatology suggests that misoprostol is superior to PPIs for gastric ulcer prevention (ulcer rates: 15 vs 43-47 per 100 patient-years), but poorly tolerated due to diarrhea 5

Comparative Safety and Drug Interactions

• The National Institute for Health and Care Excellence states that among NSAIDs, ibuprofen, etodolac, and nabumetone demonstrate superior GI safety compared to diclofenac and other agents with prominent enterohepatic circulation 1, 4
• The American Academy of Family Physicians recommends monitoring for increased INR by up to 15% and GI bleeding risk increases 3-6 fold when diclofenac is used with anticoagulants 6